GSK signs new agreement with China's Chimagen for trispecific T-cell engager targeting blood cancers

GSK, the UK‑based pharmaceutical company, has entered into a fresh licensing agreement with Chinese biotech Chimagen Biosciences. The partnership focuses on a trispecific T‑cell engager designed for the treatment of blood cancers.

The deal follows a prior licensing arrangement between the two firms that was announced two years ago. While the specific financial terms were not disclosed, the collaboration is expected to advance the candidate through pre‑clinical and early clinical development.

Both companies said the agreement reflects a shared interest in expanding immunotherapy options for hematologic malignancies, and it adds to GSK's growing pipeline of cell‑based therapies.

Details on timelines, regulatory pathways, or potential commercialization plans were not provided in the announcement.